Glaukos (NYSE:GKOS) today said it completed its acquisition of Avedro for an undisclosed amount. Avedro develops single-use drug formulations that are designed to strengthen corneal tissues and stop the progression of degenerative corneal ectatic disease keratoconus. “Today marks an important day for Glaukos as Avedro will serve as the cornerstone of our new corneal health franchise,” […]
On mixed Q2 results, Glaukos announces Avedro buy
Glaukos (NYSE:GKOS) posted its second-quarter financial results this week and reported that it plans to acquire Avedro in an effort to build out its corneal health franchise. Avedro develops single-use drug formulations designed to strengthen corneal tissue and stop the progression of a degenerative corneal ectatic disease known as keratoconus. According to the Mass.-based company, the […]
Avedro application needs more work, FDA says
Massachusetts ophthalmic devices maker Avedro has some issues to address before the company can move forward with an FDA New Drug Application for its light-based cross-linking product for treatment.
